WATERTOWN, Mass.--(BUSINESS WIRE)--Acusphere, Inc. (Nasdaq: ACUS) announced today that the Company has trained all of the echo blinded readers in the RAMP-2 trial to increase their sensitivity, the ability to detect coronary heart disease, in stress echo images enhanced by its lead product candidate, Imagify™ (formerly known as AI-700). In connection with this training, all RAMP-2 echo blinded readers read with higher sensitivity than prior to the training, while maintaining high accuracy, the ability to correctly determine the presence or absence of disease. All of these echo blinded readers read at accuracy, sensitivity and specificity levels that were similar to that of the nuclear reader in RAMP-1.
